drugset / Trial / NCT05140200
Study of GSK3511294 in Healthy Chinese Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants
Timeline
- Start
- 2021-12-10
- Primary completion
- 2022-12-23
- Completion
- 2022-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Depemokimab | Protein / enzyme biologic | 100 mg | Subcutaneous |
| Subject | Depemokimab | Protein / enzyme biologic | 300 mg | Subcutaneous |